Background: Esophageal dysfunction and gastro-esophageal reflux disease (GERD)
| INTRODUCTION
Patients with systemic sclerosis (SSc) have dysfunction of multiple organ systems including the skin, vasculature, and gastrointestinal tract. Up to 80% of patients with SSc have esophageal involvement. 1 The most common esophageal disorder in SSc patients is gastroesophageal reflux disease (GERD). 2 Complications from esophageal reflux can be serious and include bleeding, stricture formation, Barrett's esophagus, and adenocarcinoma. 2 In patients with SSc, uncontrolled acid reflux may contribute to the progression of interstitial lung disease. 3, 4 Furthermore, reflux severity may predict survival status in SSc patients awaiting lung transplant. Several pathophysiologic mechanisms contribute to acid reflux in SSc patients. Patients may develop distal esophageal smooth muscle atrophy and fibrosis, which can subsequently cause decreased lower esophageal sphincter (LES) pressure and loss of esophageal peristalsis. 6 These physiologic changes can lead to increased esophageal acid exposure. The combination of hypotensive LES and distal esophageal aperistalsis is often referred to as scleroderma esophagus, although these changes are not specific to SSc disease, and SSc patients can have a range of motility abnormalities on high-resolution manometry (HRM) testing. 7, 8 Despite the known risks of GERD in SSc patients, optimal treatment regimens for these patients have not been standardized. 2, 6, 9 Many patients are prescribed a proton pump inhibitor (PPI) to suppress gastric acid only when they endorse symptoms of GERD, although esophageal involvement in SSc is often asymptomatic. 
| MATERIALS AND METHODS

| Patients
The study protocol was approved by the Northwestern University 
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After matching for PPI dose and formation, patients were subsequently matched by size of hiatal hernia, age, and gender. All authors had access to study data and reviewed and approved the manuscript. The pH-impedance recordings were analyzed using dedicated software ("Bioview Analysis," version 5.5.5.1; Sandhill Scientific, Inc.).
| Combined pH-impedance
The pH-impedance tracings were manually reviewed to confirm reflux episodes defined by a retrograde 50% drop in impedance values. Nadir pH of each liquid and mixed reflux event was measured. Liquid and mixed reflux events were then classified as acidic when the pH dropped below 4, as weakly acidic when the nadir pH was between 4 and 7, and as weakly alkaline when the nadir pH was above 7. Acid exposure time (AET) was calculated as total time in the distal esophagus at pH <4
(including only pH drops associated with reflux events detected with impedance) divided by recording duration and expressed in percent.
Key Points
• Esophageal dysfunction and reflux are common in patients with systemic sclerosis (SSc) yet the effectiveness of proton pump inhibitor (PPI) therapy has not been systematically studied in this population. This study evaluated esophageal reflux in SSc patients on high-dose PPIs using esophageal pH testing.
• This study demonstrated that SSc patients have significant esophageal acid exposure despite high-dose PPI therapy, which may be related to ineffective esophageal clearance.
• Systemic sclerosis patients may require adjunctive therapies to PPIs to control their acid reflux.
Other recorded parameters included longest AET (measured in minutes), median bolus clearance time (seconds), and DeMeester score.
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The total number of acid, weakly acid, and non-acid reflux events was also noted. Mean nocturnal baseline impedance (MNBI) (measured in ohms) were measured at 1, 2, and 3 hours after sleep onset with the mean value of the three measures recorded. 
| Statistical analysis
| RESULTS
| Patients characteristics
Sixty SSc patients were initially identified from the esophageal registry. Eleven were excluded after determining they were not actually taking BID PPI at time of pH-impedance testing. Six were excluded as they did not meet 2013 ACR Criteria for SSc. Four were excluded for being post-surgery (2 Nissen fundoplications, 2 lung transplants). One was excluded for having a hiatal hernia >5 cm. 
| Combined pH-impedance characteristics
A detailed description of the pH-impedance findings in SSc patients
and controls is found in Table 2 . Systemic sclerosis patients had significantly higher total AET (%) compared to controls ( Figure 1A ).
Twenty-three of 38 (61%) SSc patients, compared to 7 of 38 (18%) controls, had a total AET ≥4.5% (P < .001). Twenty-one of 28 (55%) SSc patients, compared to 6 of 38 (16%) control patients, had a total AET >6% (P < .001). In contrast, the controls had higher total reflux events than the SSc patients ( Figure 1B) , and this finding held true for both acid and weakly acid reflux events. Systemic sclerosis patients had higher acid exposure than controls regardless of hiatal hernia size.
Acid exposure times were 6.5 (1.3-18.7) for SSc patients without a hiatal hernia, 12.9 (3.5-22.8) for SSc patients with a 1-2 cm hernia, and 3.9 (2.1-26.2) for patients with a 3-4 cm hernia. In contrast, AETs were 1.5 (0.5-3.8) for controls without a hernia, 1.8 (0.7-4.6) for controls with a 1-2 cm hernia, and 2.4 (0.2-5.0) for controls with a 3-4 cm hernia. Mean nocturnal baseline impedance was significantly lower in SSc patients compared to controls.
| Manometric characteristics
Esophageal manometry was performed in 31 SSc patients and 32 controls. Details on the manometric findings are found in Table 3 .
Seventy-two percent of patients with SSc had absent contractility on manometry, whereas no control patients had this finding. Additionally, 72% of control patients had normal motility, compared to only 10% of SSc patients. Figure 2 shows the association between motility diagnosis and AET for SSc patients and controls.
Systemic sclerosis patients had lower basal EGJ pressures, as measured at end expiration and with the EGJ-contractile integral, than controls. Twenty-two (71%) SSc patients had a hypotensive EGJ, defined as EGJ end-expiratory pressure <10 mm Hg. Eighteen (58%) of these patients had the typical findings of "scleroderma esophagus," defined as hypotensive EGJ with absent contractility. Patients with the "scleroderma" pattern had a median AET of 12.1% (IQR 4.1-24.3).
| DISCUSSION
Gastro-esophageal reflux disease is a common and serious problem in patients with SSc. To our knowledge, this is the first study to assess T A B L E 2 Combined pH-impedance findings and characterize the extent of esophageal reflux on high-dose PPI therapy in SSc patients using combined pH-impedance testing. We found that despite high-dose PPI, 61% of SSc patients had an AET ≥4.5% and 55% of SSc patients had an AET >6%. These AET values were significantly higher than in a matched-control cohort of patients also on high-dose PPI. These AET values were also much higher than in historical cohorts of GERD patients, in which only 7% have persistent abnormal esophageal exposure on ambulatory 24-hour pH testing while on BID PPI. 14 Compared to controls, SSc patients were also found to have longer AET, longer median bolus clearance time, and lower MNBI. However, the control group of patients had significantly more individual acid reflux events than the SSc patients. 24 However, the study lacked impedance-pH metry, which is the gold standard for the assessment of GERD. 24 Furthermore, all patients were studied off PPI therapy. Given that many SSc patients are on a PPI for their upper gastrointestinal (GI) symptoms, and some experts recommend all SSc patients be on PPI, the findings have limited generalizability. 6 The differences in reflux parameters between the SSc patients and controls suggest that the underlying mechanism of reflux may be dis- and negatively correlated with pulmonary function. 25 The controls had higher individual reflux events, which speaks to a different mechanism of reflux in this population. Our data also suggest that additional aspiration precautions should be considered in SSc patients.
Increased esophageal acid exposure in SSc patients despite highdose PPI therapy has several diagnostic and treatment implications.
Among SSc patients with persistent reflux symptoms despite PPI use, physicians should have a low threshold to escalate therapy to highdose and high potency PPIs and utilize esophageal pH-impedance F I G U R E 2 Association between manometric diagnosis and acid exposure times (AETs). Breakdown of total esophageal acid time by motility diagnosis in both systemic sclerosis (SSc) and control patients. There was one additional SSc patient with an achalasia motility pattern and an AET of 1.3% not represented on the figure. EGJ, esophagogastric junction
